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Abstract 
Accumulation of fibrillar amyloid -protein (A) in blood vessels of the brain, a 
condition known as cerebral amyloid angiopathy (CAA), is a common pathology of 
the elderly, a prominent comorbidity of Alzheimer’s disease and driver of vascular 
cognitive impairment and dementia (VCID). Although several transgenic mouse 
lines have been generated that develop varying levels of CAA, consistent models 
of associated cerebral microhemorrhage and vasculopathy observed clinically 
have been lacking. Reliable preclinical animal models of CAA and 
microhemorrhage are needed to investigate the molecular pathogenesis of this 
condition. Here, we describe the generation and characterization of a novel 
transgenic rat (rTg-DI) that produces low levels of human familial CAA Dutch/Iowa 
E22Q/D23N mutant A in brain and faithfully recapitulates many of the pathological 
aspects of human small vessel CAA. rTg-DI rats exhibit early-onset and 
progressive accumulation of cerebral microvascular fibrillar amyloid accompanied 
by early-onset and sustained behavioral deficits. Comparable to CAA in humans, 
the cerebral microvascular amyloid in rTg-DI rats causes capillary structural 
alterations, promotes prominent perivascular neuroinflammation and produces 
consistent, robust microhemorrhages and small vessel occlusions that are readily 
detected by magnetic resonance imaging. The rTg-DI rats provide a new model to 
investigate the pathogenesis of small vessel CAA and microhemorrhages, to 
develop effective biomarkers for this condition and to test therapeutic 
interventions. 
 
Introduction 
Cerebral amyloid angiopathy (CAA) is a common cerebral small vessel disease 
that involves the accumulation of amyloid -protein (A) primarily in small- and medium-
sized arteries and arterioles of the meninges and cerebral cortex as well as along the 
capillaries of the cerebral microvasculature 1-6. CAA has been shown to be present, in 
varying degrees, in nearly 80% of elderly individuals 7,8. With the involvement of A, it is 
not surprising that CAA is a very common vascular comorbidity in patients with 
Alzheimer’s disease (AD) 3,7-9.  Even when controlling for confounders including AD, CAA 
is a significant contributor to vascular-mediated cognitive impairment and dementia 
(VCID) and is independently associated with worse cognition and dementia 7,8,10-13. In 
addition to the sporadic cases of CAA and the prominent CAA that is observed in AD, 
several monogenic, familial forms of CAA exist that result from mutations that reside 
within the A peptide sequence of APP gene including the Dutch E22Q and Iowa D23N 
variants 12-14. 
CAA can present as two prominent forms known as CAA type-1 and CAA type-2 
6. In CAA-type 2 the amyloid deposition is largely restricted within the vessel wall of the 
meningeal and cortical arterioles and generally does not promote perivascular 
neuroinflammation 5,6,15. In contrast, CAA type-1 involves amyloid deposition along 
transitional cerebral microvessels and capillaries and is present in nearly half of AD cases 
5,6. In contrast to larger vessel CAA type-2 where the amyloid is largely confined within 
the vessel wall, CAA type-1 results in penetrance of the fibrillar amyloid deposits into the 
surrounding brain parenchyma – so called “dyshorric amyloid” – a feature which promotes 
a strong perivascular neuroinflammatory response 5,6,16,17. In particular, cerebral 
microvascular amyloid deposition is often correlated with worse cognition and dementia 
in individuals afflicted with AD and sporadic/familial CAA disorders 18-22.  
Transgenic mice, which robustly over-express human APP in brain and develop 
cerebral A deposits, have been a significant advancement for the study of the 
pathogenic effects of brain A accumulation in vivo. Several well-established transgenic 
mouse lines have been developed that over-produce human A peptides in brain that 
develop age-dependent accumulation of parenchymal A deposits with varying degrees 
of CAA and associated vasculopathies 23-26. Specifically, transgenic mouse lines were 
developed that express human APP in brain harboring one or more of the familial CAA 
mutations 27,28. Importantly, these familial CAA transgenic mouse lines revealed the 
specific role of CAA in neuroinflammation and VCID 29-32. However, as with all mouse 
models, CAA transgenic mice possess some significant limitations to more fully 
recapitulate and study the equivalent human condition. In particular, consistent and robust 
microbleeds have been elusive in most CAA mouse models. Therefore, more appropriate 
animal models of small vessel CAA are necessary to progress our understanding of the 
pathogenesis, its contribution to structural changes in the brain and VCID.  
Here we describe our efforts to generate and characterize a new transgenic rat 
model (rTg-DI) for small vessel CAA. We demonstrate that rTg-DI rats exhibit early-onset 
and progressive accumulation of cerebral microvascular fibrillar amyloid accompanied by 
behavioral deficits. Fibrils seeded from the vascular amyloid isolated from rTg-DI rats 
exhibit intense bands in Fourier transform infrared (FTIR) spectra characteristic of 
antiparallel -sheet similar to that previously observed for human cerebral vascular 
amyloid 33. Moreover, in rTg-DI rats the cerebral microvascular A deposits cause 
capillary structural changes, promote prominent perivascular glial activation and produce 
consistent, robust microhemorrhages with small vessel occlusions that are readily 
detected by magnetic resonance imaging. 
Materials and Methods 
Generation of Transgenic Rats All work with animals followed National Institutes of 
Health guidelines and was approved by the University of Rhode Island, Yale University 
and Stony Brook University Institutional Animal Care and Use Committees. A pcDNA3 
vector containing 2.1 kb of human APP (isoform 770) cDNA was used to introduce the 
mutations Swedish K670N/M671L, Dutch E693Q, and Iowa D694N using the 
QuikChange kit (Stratagene, La Jolla, CA). The APP770-SwDI cDNA was amplified by 
PCR using primers containing the NheI 5-linker and SacII 3-linker. The PCR product was 
digested and subcloned between exons II and IV of a Thy1.2 expression cassette using 
NheI and SacII restriction sites. The completed construct was entirely sequenced to 
confirm its integrity. The 9-kb transgene was liberated by NotI/PvuI digestion, purified, 
and microinjected into pronuclei of Sprague-Dawley single cell embryos. Founder rats 
were identified by Southern blot analysis of tail DNA. Transgenic offspring were 
determined by PCR analysis of tail DNA using the following primers specific for human 
APP: 5’-CCTGATTGATACCAAGGAAGGCATCCTG-3’ and 5’-
GTCATCATCGGCTTCTTCTTCTTCCACC-3’ (generating a 500-bp product). All 
subsequent analyses were performed with heterozygous transgenic rats.  
 
Immunoblot Quantitation of APP. Rat forebrain tissues were homogenized in 10 
volumes of 50 mM Tris-HCl (pH 7.5) containing 150 mM NaCl, 1% SDS, 0.5% Nonidet P-
40, 5 mM EDTA, and proteinase inhibitor mixture (Roche Applied Science, Indianapolis, 
IN). The tissue homogenates were clarified by centrifugation at 14,000 x g for 10 min. 
Protein concentrations of the resulting supernatants were determined using the BCA 
protein assay Kit (Fisher Scientific, Houston, TX). The levels of APP in the forebrain 
tissue homogenates were determined by performing quantitative immunoblotting as 
described 27. Samples were probed either with monoclonal antibody P2-1, which is 
specific for human APP 34, or with monoclonal antibody 22C11 (Chemicon International, 
Inc., Temecula, CA), which detects both rat and human APP. Bands corresponding to 
APP were measured using a LICOR imaging system (Lincoln, NE). 
 
Quantitation of A Peptides Soluble pools of Aβ40 and Aβ42 were determined by 
performing specific ELISAs on carbonate extracted rat forebrain tissue and subsequently 
the insoluble Aβ40 and Aβ42 levels were determined by ELISA of guanidine lysates of 
the insoluble pellets resulting from the carbonate extracted rat brain tissue as described 
35,36. In the sandwich ELISAs Aβ40 and Aβ42 were captured using their respective 
carboxyl-terminal specific antibodies mAb2G3 and mAb21F12 and biotinylated m3D6, 
specific for human Aβ, was used for detection 35. Cerebral microvessels were isolated 
from rat forebrains as described 27,37. The levels of cerebral microvascular A40 and A42 
levels were measured in guanidine lysates of the brain microvessels isolated from rTg-DI 
rats. Each rat brain or microvessel lysate was measured in triplicate and compared to 
linear standard curves generated with known concentrations of human Aβ using a 
Spectramax M2 plate reader (Molecular Devices, Sunnyvale, CA).  
 
Isolation of cerebral capillary amyloid seeds. Brain capillaries were isolated from the 
cortices of twelve months old rTg-DI rats as described 27,37. The isolated microvessels 
were analyzed microscopically by staining with thioflavin S and immunolabeling with an 
antibody to collagen IV to confirm the isolation of amyloid-containing microvessels. The 
remaining microvessels were treated with 3 mg/ml collagenase at 37 oC overnight. The 
collagenase treated samples were centrifuged at 16,000 x g for 5 min and the resulting 
pellet was washed twice with TBS. The amyloid pellet was resuspended in TBS and again 
analyzed microscopically by staining with thioflavin S and immunolabeling with an 
antibody to collagen IV to confirm the isolation of vascular amyloid deposits and the 
absence of microvessels. 
 
Seeding of fibrils from vascular amyloid.  For the preparation of fibrils from isolated 
vascular amyloid, isolated vascular amyloid was sonicated for using a Fisher Scientific tip 
sonicator at 30% power in four 10 sec bursts. Monomeric (synthetic) A40-WT peptide 
was added to the seeds in 3 steps at 1 h intervals. The A40-WT peptide was synthesized 
using N-t-Boc chemistry on an ABI 430A solid-phase peptide synthesizer (ERI Amyloid 
Laboratory, Oxford, CT) and purified by high performance liquid chromatography (HPLC). 
Based on analytical reverse phase HPLC, the peptide purity was greater than 98%. The 
mass of the purified peptide was measured using matrix-assisted laser desorption or 
electrospray ionization mass spectrometry and was consistent with the calculated mass 
for the peptide. The peptides were isotopically labeled with 1-13C at Leu17, Ala21, Gly33 
and Gly37 for FTIR measurements. Purified, lyophilized A peptides were aliquoted in 
hexafluoroisopropanol and freeze-dried for at least 4 days with a vacuum of 25 mTorr.  
For preparing monomeric A, the peptide was dissolved in 50 mM NaOH at a 
concentration of 2.2 mM, then diluted in 10 mM phosphate buffer (pH 7.4) at low 
temperature (4 °C). The Aβ solutions were then filtered with a 0.2-micron cellulose acetate 
filter to remove insoluble aggregates. The Aβ concentration was determined by the 
absorption at 270 nm using a molar extinction coefficient of ε=1405 cm-1·M-1. 
 
Fluorescence spectroscopy. Thioflavin T fluorescence measurements were performed 
on a SpectraMax M2 spectrofluorimeter plate reader. The Aβ peptide concentration was 
100 M and the thioflavin T concentration was 50 M. Thioflavin T fluorescence was 
monitored every 15 sec with excitation, emission and automatic cutoff wavelengths of 
446, 490 and 475 nm, respectively.   
 
FTIR spectroscopy.  FTIR spectra were obtained on a Bruker Vertex 70 spectrometer 
using a germanium attenuated total reflection (ATR) plate with a spectral resolution of 4 
cm-1.  Samples were prepared by drying a 50-100 l of peptide solution on the plate 
surface.  
 
Tissue Preparation. Rats were euthanized at designated time points and perfused with 
cold-PBS, forebrains were removed and dissected through the mid-sagittal plane. One 
hemisphere was either immersion-fixed with 70% ethanol overnight and subjected to 
increasing sequential dehydration in ethanol, followed by xylene treatment and 
embedding in paraffin. Alternatively, brains were fixed with 4% paraformaldehyde 
overnight at 4oC and subjected to increasing concentrations (10, 20, 30%) of sucrose in 
PBS, then embedded in OCT compound (Sakura Finetek Inc., Torrance, CA) and snap-
frozen in dry ice. Sagittal sections were cut at 10 µm thickness using a Leica RM2135 
microtome (Leica Microsystems Inc., Bannockburn, IL), placed in a flotation water bath at 
40°C, and then mounted on Colorfrost/Plus slides (Fisher Scientific, Houston, TX).  In 
some cases, coronal sections were cut at 20 m thickness from frozen brains using a 
Leica CM1900 cryostat (Leica Microsystems Inc.), stored in PBS with 0.02% sodium 
azide at 4oC. 
Immunohistochemical Analysis Antigen retrieval was performed by treating the tissue 
sections with proteinase K (0.2 mg/ml) for 10 min at 22 °C. Primary antibodies were 
detected with Alexa Fluor 594-conjugated donkey anti-rabbit or Alexa Fluor 488-
conjugated goat anti-mouse secondary antibodies (1:1000). Staining for fibrillar amyloid 
was performed either using Amylo-Glo as described by the manufacturer (Biosensis Inc., 
Thebarton, South Australia) or using thioflavin S. The following antibodies were used for 
immunohistochemical analysis: mAb66.1 (1:250), which recognizes residues 1-5 of 
human A 38; mAb2B4 to detect A42 (1:1000) and rabbit polyclonal antibody to detect 
A40 (1:200; Biosource, Camarillo, CA) A42, respectively; rabbit polyclonal antibody to 
collagen type IV to visualize cerebral microvessels (1:100; ThermoFisher, Rockford, IL); 
and rabbit polyclonal antibodies to GFAP (1:200; Dako, Santa Clara, CA) and Iba-1 
(1:200; Fujifilm Wako Pure Chemical, Osaka, Japan) for detection of astrocytes and 
microglia, respectively. Prussian blue iron staining was performed to detect hemosiderin 
deposits reflecting signs of previous microhemorrhage 39,40. Von Kossa calcium staining 
was used to detect small vessel occlusion/calcifications in the brain 41. In this case, tissue 
sections were counterstained with pararosanline.  
Quantitative Analysis of Vascular Pathologies The percent area amyloid coverage of 
cerebral microvessels, percent area iron staining and the numbers of occluded/calcified 
vessels in the frontotemporal cortex, thalamic, and hippocampal regions was determined 
in rats at each of the specified ages using stereological principles as described 42. 
Cerebral microvessel tortuosity in different brain regions was determined by 
immunolabeling the vessels in brain tissue sections, measuring both the traced actual 
vessel length and the direct straight line, end to end vessel length and dividing the actual 
length/direct length. 
Novel Exploration Behavioral Task A novel exploration paradigm was included to 
measure perceptual slowing as represented in a slowed rate of stimulus encounters. This 
was a common deficit observed in the similar Tg-SwDI mouse model 31.  Typically, 
animals were placed in the open field apparatus to explore four novel and distinct objects 
for a 5-min trial period. Interaction with an object was scored by the AnyMazetm software 
as entering into a predetermined zone surrounding the object. 
 
Magnetic Resonance Imaging Analysis All rats were deeply anesthetized with 
ketamine/xylazine (75 mg/kg / 10 mg/kg) i.p. followed by trans-cardial perfusion fixation. 
First, vascular perfusion was conducted with 0.1% heparin/PBS (20cc/min for 5 min); 
followed by 5% Magnevist in 10% buffered formalin solution (120 ml/rat at 20cc/min) using 
a Pharmacia LKB P-1 peristaltic pump. Following perfusion fixation of the 12 months old 
male rTg-DI and wild-type rats, the brains were removed from the skull with great care so 
as to not damage the brain parenchyma. The brain specimens were immersed in PBS for 
≥ 4 days. All MRI acquisitions were performed on a Bruker 9.4T/30 magnet (Bruker 
BioSpin, Billerica MA) with BGA-12SHP imaging gradient system interfaced to an Avance 
III console controlled by Paravision 5.1 software. For the post-mortem high resolution 
scanning we used a cryogenically cooled RF coil as a transmit and receive. The brain 
specimens were imbedded in fomblin (HT230-7K, Fluids & Greases, Kurt J. Lesker, 
Jefferson Hills, PA) and underwent MRI using a 3D gradient echo sequence with the 
following imaging parameters: TR/TE/FA=100ms/7~30ms/25° NEX=1 resolution= 
0.08x0.08x0.08mm. The brain specimens were subsequently processed and stained for 
hemosiderin deposits as described above. The stained whole brain slices were digitized 
using an optical microscope (All-in-One Fluorescence Microscope BZ-X700), allowing the 
entire brain slice to be used for matching with the corresponding high-resolution post-
mortem MRIs. The optical resolution achieved on the digitized brain slices was 0.377 
µm/pixel. 
The MRIs were displayed as isotropic 3D volumes using Amira software (Version 
6.2). 3D MRIs acquired with a TE of 7ms and 18ms were used for the matching process. 
The process to match the MRIs to the corresponding histological brain slice involved 
several computational steps; and in all processing the histological brain slice served as 
the master template or ‘reference’ and the 3D MRI was manipulated to match it. First, 3-
5 histological slices of interest were chosen which included thalamic iron staining-positive 
areas of micro-hemorrhages. Using the ‘slice’ feature in Amira, the MRI slice plane that 
best matched the histological slice - (based on anatomical landmarks such as the shape 
of the hippocampus, the corpus callosum, the fimbria and the shape of the ventral surface) 
were defined. Using rigid matching (scaling in x- and y-directions) the MRI was matched 
to the histological slice. Finally, the histological slice was overlaid onto the matched 2D 
MRI to determine the MRI signatures associated with the iron stain-positive areas. 
 
Statistical Analysis Histological and biochemical data were analyzed by t-test at the 
0.05 significance level.  Behavioral testing data were analyzed by t-tests and the 
performance of each subject for each testing day was the average latency of the two 
trials. 
 
Results 
Low Level Expression of Human CAA Mutant APP in Brain Results in Progressive 
and Extensive Microvascular CAA 
To target production of human chimeric Dutch/Iowa CAA mutant in neurons of rat 
brain we took a similar approach that was successfully used in the previous generation 
of our Tg-SwDI mouse line 27. We used the neuronal-specific Thy1.2 expression cassette 
to drive expression human APP harboring the familial AD Swedish K670N/M671L 
mutations and the familial CAA Dutch E693Q and Iowa D694N mutations in neurons in 
the rat brain. The Swedish APP mutations were included solely to enhance -secretase 
processing and production of A peptides 43. The familial CAA Dutch and Iowa mutations 
were included in the transgene to yield chimeric Dutch/Iowa CAA mutant A peptides in 
brain which exhibit markedly enhanced fibrillogenic and vascular pathogenic properties 
44,45. The transgenic rats (rTg-DI) were generated by microinjection of the human 
APP770-SwDI construct into oocytes in a pure Sprague-Dawley background. The 
presence of the human APP transgene was confirmed in founder and subsequent 
offspring rats by PCR analysis. All rTg-DI rats used in the subsequent characterization 
experiments were heterozygous for the human APP transgene. 
Two months old rTg-DI rats were evaluated for expression of the human APP 
transgene using the human APP-specific monoclonal antibody P2-1 34. 
Immunohistochemical analysis presented in Figure 1A-F shows that human APP 
expression was evident throughout the cortex, hippocampus and thalamus and was 
restricted to neurons. Immunoblot analysis using mAbP2-1 confirmed that human APP 
transgene expression was only observed in rTg-DI rats (Figure 1G). Subsequent 
quantitative immunoblot analysis using the total (rat + human) APP-specific mAb22C11 
showed that human transgene APP expression was modest and only about 50% higher 
than the levels of endogenous rat APP seen in wild-type rats (Figure 1H). 
The accumulation of human A peptides was measured in rTg-DI brains as they 
aged over 12 months. A sandwich ELISA format was used that detected only human A 
peptides 35,36. As the rTg-DI rats aged from 3-12 months there was a progressive increase 
in the amounts of soluble A40 in brain whereas the amounts of soluble A42 remained 
fairly constant over this time period (Figure 1I). The majority of soluble A peptides 
(>90%) at each age were the shorter A40 isoform. On the other hand, there was a 
progressive accumulation of both insoluble A40 and A42 as the rats aged (Figure 1J). 
Again, the vast majority of accumulated insoluble A peptide was the shorter A40 
isoform. These findings indicate that despite the low level of transgene human APP 
expression there is an early-onset and progressive accumulation of Dutch/Iowa CAA 
mutant A peptides in the brains of rTg-DI rats. 
 Early-Onset and Extensive Accumulation of Cerebral Microvascular Amyloid is 
Associated with Behavioral Impairments and Exhibits a Characteristic Anti-Parallel 
Alignment. 
 Since insoluble levels of cerebral A markedly increase with age in rTg-DI rats the 
compartmental distribution of fibrillar amyloid was examined over time. Figure 2 shows 
that as early as 3 months of age there was notable accumulation of cerebral 
microvascular amyloid in the cortical, hippocampal and thalamic regions of the brain. 
Further, as the rTg-DI rats aged to twelve months there was a dramatic increase in 
cerebral microvascular amyloid deposition with nearly 45% and 70% of capillaries 
covered in fibrillar amyloid in the thalamic and hippocampal regions, respectively (Figure 
2J). Although the levels of capillary CAA were somewhat lower in the cortical areas still 
nearly 30% of vessel surface was covered. Importantly, Figure 2K shows that these early 
levels of capillary CAA in the rTg-DI rats were associated with the characteristic slowing 
in the manner of exploration of unique objects arrayed in an open field (i.e. the novel 
object exploration task) consistent with a form of perceptual slowing likely to result from 
cortico-thalamic and hippocampal dysfunction and present in CAA 7. 
Immunohistochemical analysis revealed that the vast majority of cerebral 
microvascular amyloid was comprised of A40 (Figure 3A-C). Further, ELISA analysis of 
isolated cerebral microvessels from rTg-DI rats confirmed that nearly 90% of the 
accumulated amyloid was composed of A40 peptide (Figure 3D,E). Fibrillar 
microvascular amyloid seeds were isolated from rTg-DI rats (Figure 3F) and FTIR 
spectroscopy revealed a strong -sheet secondary structural component characteristic of 
amyloid fibrils as indicated by the prominent spectral peak at ≈1632 cm-1 (Figure 3G). 
Whereas wild-type A40 peptide slowly formed fibrils, the addition of the isolated 
microvascular amyloid seeds promoted rapid fibril assembly of wild-type A40 as assayed 
by thioflavin T fluorescence spectroscopy (Figure 3H). The rapid increase in fluorescence 
argues that the A monomers are using the structural template provided by the seeds 
as they associate with the growing fibrils.  Recently, we found that fibrils seeded from 
cerebral vascular amyloid exhibited intense FTIR bands characteristic of antiparallel -
strand structure 33.  Notably, the newly formed seeded wild-type A40 fibrils from rTg-DI 
microvascular amyloid exhibit a similar anti-parallel signature as reflected by the strong 
FTIR spectral band at ≈1607 cm-1 (Figure 3I).  
 
Accumulation of Cerebral Microvascular Amyloid in rTg-DI Rats Promotes Capillary 
Structural Changes and Perivascular Inflammation  
 The prominent accumulation of cerebral microvascular amyloid in rTg-DI rats 
caused pronounced structural changes to cerebral capillaries compared to similarly aged 
wild-type rats. These capillary changes included the appearance of numerous “string 
vessels”, which are remnants of capillaries with no endothelial cells 46, and prominent 
vessel fragmentation (Figure 4B). These structural changes were accompanied by a 
significant (p < 0.001) increase in the tortuosity of the cerebral capillaries in the affected 
brain regions further demonstrating the deleterious effects of vascular amyloid 
accumulation (Figure 4C). Additionally, there was a significant (p < 0.001) increase in 
capillary area in the thalamic region and an increased trend in the other brain regions 
which may reflect the increased tortuosity (Figure 4D). 
We also observed that cerebral microvascular amyloid in rTg-DI rats, which 
engages the surrounding brain parenchyma, is associated with a strong 
neuroinflammatory response reflected by a robust increase of perivascular reactive 
astrocytes (Figure 5B) when compared to similarly aged wild-type rats devoid of 
microvascular amyloid (Figure 5A). Likewise, an elevated number of perivascular 
activated microglia are present in rTg-DI rats in areas with microvascular CAA (Figure 
5D). It was also noted that the lower number of microglia present in the similarly aged 
wild-type rats were in the resting ramified surveillance mode with numerous extended 
processes (Figure 5C) whereas the elevated numbers of microglia in rTg-DI rats exhibited 
a bushy, activated morphology actively engaged with the fibrillar amyloid deposits on the 
cerebral capillaries (Figure 5D). These findings indicate that the presence of prominent 
cerebral microvascular amyloid in rTg-DI rats is accompanied by structural deterioration 
of brain capillaries and a robust increase in activated perivascular glial cells.  
 
Robust Microhemorrhages and Small Vessel Occlusions are Detected by MRI in 
rTg-DI Rats 
  A prominent clinical feature of CAA in humans is the presence of cerebral 
microbleeds 1,2. The presence of microbleeds was histochemically evaluated by Perl’s 
staining for perivascular hemosiderin deposits in groups of progressively aged rTg-DI 
rats. Evidence of cerebral microbleeds was observed in the cortical and hippocampal 
regions of 12 months old rTg-DI rats (Figures 6A and 6B, respectively). However, 
microbleeds were particularly abundant in the thalamic region of the brain with various 
presentations of perivascular iron deposits including tightly-associated crescent shaped 
deposits (Figure 6C), complete circumferential involvement (Figure 6D), indications of 
multiple bleeds in several adjacent microvessels (Figure 6E) and more diffuse 
perivascular iron deposits (Figure 6F). Since it was often difficult to discriminate between 
individual and grouped microbleeds we measured the area of iron deposition in the 
different brain regions at 6 and 12 months. As shown in Figure 6G, signs of microbleeds 
in the cortex were not observed at 6 months and were low at 12 months. However, in the 
hippocampus small areas of microbleeds were detected at 6 months and this increased 
as the rTg-rats aged to 12 months. Most notably, in the thalamus there was clear evidence 
of microbleeds at 6 months which dramatically increased at 12 months of age with >1% 
of the total thalamic area covered with perivascular iron deposits. Although microbleeds 
are numerous in 12 months old rTg-DI rats large macrobleeds have not been observed 
at this age.  
 Small vessel occlusions and calcifications are other microvasculopathies observed 
in CAA patients 2,47,48. Interestingly, in the thalamic region of prevalent microbleeds in 
rTg-DI rats we noted numerous occluded microvessels (Figure 7A). Calcium staining of 
adjacent brain tissue sections indicated calcifications in these small vessel occlusions 
surrounded by areas of fibrinoid necrosis (Figure 7B). These microvascular occlusions 
were bilateral and largely restricted to the ventral posterior lateral nucleus of the thalamic 
region (Figure 7C). The overall numbers of these thalamic small vessel occlusions were 
quantified in rTg-DI rats as they aged from 3 to 12 months of age. As shown in Figure 7D, 
the occlusions were extremely rare or absent at 3 months of age. However, at 6 and 12 
months the numbers markedly increased to ≈40 and ≈115 small vessel occlusions, 
respectively in this thalamic region. At each age the majority of the vessel occlusions were 
in capillaries but occasionally larger microvessels were also occluded. 
 We next performed studies in rTg-DI rats to characterize the microhemorrhages in 
situ using in vitro MR microscopy. Figure 8 shows the results of MRI-to-histology matching 
from a 12 months old rTg-DI rat with documented thalamic microhemorrhages and small 
vessel occlusions. A 2D T2*-weighted MRI (TE=7ms) (Figure 8A) was matched to the 
corresponding Perl iron-stained histological slice (Figure 8B). The dense dark areas in 
the thalamus shown on the T2*-weighted MRI are corresponding to the microvessels 
identified by Perl-stained iron deposits associated with the microbleeds and occluded 
vessels. The Perl-stained histological slice is overlaid on the T2*-weighted images under 
conditions where the histological slice has been rendered transparent to highlight the low 
signal intensity ‘susceptibility’ features on the T2*-weighted MRI observed in the 
thalamus, bilaterally, which is caused by presence of iron. Panels 8C and 8E are high 
magnification of the inserts in panels 8B and 8D, respectively. Figures 8F and 8G are 3-
D volume rendered MRIs of the same rat showing the brain outlined in light yellow; and 
the Perl-stain iron-positive associated low signal intensity area in the thalamus have been 
volume rendered (green) to illustrate the near-perfect bilateral symmetry of the 
microhemorrhages and occluded microvessels in the thalamic areas. Together, these 
findings indicate that rTg-DI develop numerous and consistent thalamic 
microhemorrhages and microvessel occlusions that are readily detected by T2*-weighted 
MRI. 
 
 
Discussion 
  
 CAA is a common cerebral small vessel disease of the elderly and a prominent 
comorbidity of AD that promotes and exacerbates VCID, yet our understanding of the 
condition remains limited and despite the high prevalence there is no effective treatment. 
Several transgenic mouse models, that develop varying levels of CAA, have been in use 
for more than a decade and have provided better insight into the pathogenesis of CAA 23-
32. However, their usefulness to further investigate CAA from the point of view of faithfully 
recapitulating the human condition is limited due to their biological evolutionary distance 
from humans and the small size of their brains which can be problematic for effective 
neuroimaging in vivo. Further, complicated cognitive testing to investigate VCID in the 
setting of evolving CAA can be unreliable due to temperamental variability in mice 49. 
Although naturally occurring models of CAA exist, most notably canines and non-human 
primates, the experimental use of these species for large cohort experimentation and 
testing is limited due to the cost and time needed for CAA to develop (decade or decades) 
50. Thus, there is a need for a better experimental model of CAA. The use of rats, 
specifically transgenic rats, to investigate the pathogenesis of human CNS disorders 
offers several distinct advantages over transgenic mice. First, rats are evolutionarily 4-5 
million years closer to humans 51. Thus, the genetics, physiology and brain morphology 
of rats are better suited to model human CAA. Second, the larger brain size and increased 
white-to-grey matter ratio of the rat enables structural neuroimaging studies with superior 
contrast- and signal-to-noise ratio compared to mice. Lastly, rats provide the opportunity 
for far more sophisticated cognitive testing compared to mice thereby bridging a gap in 
knowledge as to how CAA drives VCID 52. 
In the current study, we describe the generation and initial characterization of a 
novel transgenic rat model (rTg-DI) of microvascular type 1 CAA. The rTg-DI rats were 
designed from our earlier success in generating Tg-SwDI transgenic mice that develop 
early-onset and progressive cerebral microvascular amyloid deposition 27. In the rTg-DI 
rats, we similarly expressed the human APP transgene harboring the Swedish familial 
AD mutations and the -secretase cleavage site and the chimeric Dutch E693Q/Iowa 
D694N familial CAA mutations in neurons in the brain. Indeed, low level neuronal 
expression of the human APP transgene was observed in the rTg-DI rats (Figure 1). 
This phenotype is important because it signifies that our new CAA model does not require 
abnormal, vast over-expression of human APP and production of human A, that is 
commonly found in other transgenic rodent models, which can introduce potential 
confounds on neuronal function. This underscores that the robust cerebral accumulation 
of A and specific development of microvascular CAA is a consequence of the chimeric 
familial Dutch/Iowa mutations in the A peptide that is produced in the brains of these 
rats. Interestingly, the early-onset development of microvascular CAA and associated 
neuroinflammation coincides with early-onset and sustained cognitive deficits in rTg-DI 
rats and offers the promise of a unique model for the future elucidation as to how CAA 
can promote VCID. 
The type and form of amyloid that accumulates in the cerebral microvasculature of 
rTg-DI rats is remarkably similar to what is found in human CAA. For example, in contrast 
to parenchymal amyloid plaques that largely accumulate fibrillar A42 in both humans 
and rodent models, the fibrillar cerebral vascular amyloid deposits in rTg-DI rats are 
composed primarily of the shorter A40 species 53,54. In addition to the difference in the 
length of the A peptide that forms the amyloid fibrils in either parenchymal plaques or 
cerebral vascular deposits other micro-structural differences have been found. Recently, 
we found that fibrils produced from seeds of cerebral vascular fibrillar amyloid deposits 
exhibit increased intensity in FTIR spectra that is characteristic of anti-parallel structure 
of the  strands forming the backbone of the A fibrils 33. This structure is distinct from 
the parallel registry observed in parenchymal plaque amyloid fibrils 55,56. The -sheet, 
anti-parallel fibril character is also observed in the cerebral microvascular amyloid 
deposits of the rTg-DI rats (Figure 3). This important distinction between parenchymal 
and cerebral vascular amyloid fibrils likely is involved in the pathogenesis of these two 
types of deposits and may have important consequences with regards to subsequent 
pathologies associated with each lesion type. 
The accumulation of cerebral microvascular amyloid in rTg-DI rats promotes 
distinct vessel and perivascular changes that are reflected in human CAA. Structurally, 
the accumulation of microvascular amyloid causes significant alterations in capillary 
morphology including increased vessel fragmentation, occlusion and tortuosity (Figure. 
4).  It has been suggested that these types of structural alterations can impair capillary 
blood flow and may cause hypertension upstream from these sites of disruption 57. On 
the other hand, capillary tortuosity caused by microvascular amyloid can lead to poor 
perfusion and downstream infarction 22,58. Interestingly, there was an increase the 
capillary area in the thalamic region of rTg-DI rats which might reflect the measured 
increase in capillary tortuosity. Alternatively, it is possible that there is an increase in 
vascularization in response to the extensive amyloid-mediated damage to the 
microvasculature in this region. The changes in capillary morphology likely contribute to 
increased perivascular disturbances in fluid homeostasis, inflammation, thrombosis and 
microhemorrhage observed in CAA.  In line with this, the accumulation of fibrillar amyloid 
along the capillaries of rTg-DI rats induces a strong neuroinflammatory response 
characterized by activation and robust increases in perivascular astrocytes and microglia 
which is accompanied by consistent and frequent microbleeds and microvascular 
occlusions, particularly in the thalamic region. These latter thrombotic events may result 
directly from the excessive amyloid deposition in this region but are more likely to be 
related to downstream inflammatory responses triggered by amyloid accumulation. 
Currently, outside of biopsy or autopsy confirmation, the clinical diagnosis of CAA 
is based on the “Boston criteria” which relies primarily on the detection of lobar 
microbleeds based on MR imaging hypointensities resulting from perivascular 
hemosiderin 3,59. Similarly, MR imaging analysis of rTg-DI rats readily detected the 
perivascular hemosiderin associated with the prevalent thalamic microbleeds. 3-D 
reconstruction of the MR defined hypointensities illustrated the symmetrical and bilateral 
nature of these consistent thalamic microbleeds (Figure 8). These findings suggest that 
similar parameters for the “Boston criteria” diagnosis of CAA in humans can be applied 
to rTg-DI rats allowing for the opportunity to investigate the longitudinal development and 
persistence of these hallmark lesions by clinical relevant methodology. 
Although the extent of CAA, capillary structural changes and perivascular 
neuroinflammation is high in several brain regions of rTg-DI rats at six to twelve months 
it is currently unclear why the most severe associated events of microhemorrhage and 
vessel occlusion are largely restricted bilaterally to the thalamic regions. In human CAA, 
cerebral microbleeds tend to be found in lobar cortical regions, in particular the occipital 
cortex, and not so frequently in deeper brain structures. However, in cerebral autosomal 
dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), 
another type of cerebral small vessel disease, thalamic microbleeds are commonly 
observed both in humans and in the equivalent transgenic mouse model 60-62. Perhaps 
the thalamic region in rats exhibits differential blood flow or perivascular clearance 
mechanisms compared to humans and in other regions of the rat brain making this region 
particularly susceptible to excessive perivascular amyloid deposition. Alternatively, rat 
capillaries/microvessels in the thalamic areas may possess a different vascular 
environment compared to other brain regions. Future studies are needed to evaluate 
these possibilities. Although the anatomical distribution of CAA and cerebral vascular 
thrombotic lesions may be somewhat different between rTg-DI rats and humans this 
unique model provides new opportunities to investigate the pathogenic development of 
CAA and its relation of VCID. Further, rTg-DI rats provide an improved platform for the 
development of biomarkers and preclinical testing of therapeutic interventions for this 
common small vessel disease.    
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Figure Legends 
Figure 1.  Analysis of transgenic human APP expression and progressive A 
accumulation in rTg-DI rats.  
Brain sections from two months old rTg-DI rats were immunolabeled with the mouse 
monoclonal antibody mAbP2-1 to specifically detect human APP (green) and the rabbit 
polyclonal antibody NeuN to detect neurons (red). There was widespread human APP 
expression in neurons in the cortex (A,B), hippocampus (B,D) and thalamus (E,F). Scale 
bars = 10 µm (A,C,E) and 50 µm (B,D,F). (G) Immunoblot analysis of human APP 
expression in total brain homogenates from wild-type rats and rTg-DI rats. (H) 
Quantitative immunoblotting was performed to measure total APP (endogenous rat 
APP + transgenic human APP) in brain homogenates of wild-type rats and rTg-DI rats. 
The data presented are the means ± S.D. of 5 rats per each group (*p < 0.05). The level 
of transgene human APP expression is ≈50% the amount of endogenous rat APP. The 
levels of soluble (I) and insoluble (J) A40 and A42 peptides in the forebrain of 
progressively aged rats were measured by ELISA as described under “Experimental 
Procedures.” The data presented are the means ± S.D. of triplicate measurements in 5-6 
rTg-DI rats per group.     
 
Figure 2.  Progressive Accumulation of Microvascular CAA in rTg-DI Rats.  
Brain sections from rTg-DI rats at three months old (A-C), six months old (D-F) and twelve 
months old (G-I) were stained for fibrillar amyloid using thioflavin-S (green) and 
immunolabeled for collagen type IV to identify cerebral microvessels (red). Scale bars = 
50 µM. The rTg-DI rats develop early-onset and progressive cerebral microvascular 
fibrillar amyloid in the cortical, hippocampal and thalamic regions. (J) Quantitation of 
microvascular thioflavin-S positive amyloid load in different brain regions of three months 
(blue bars), six months (gray bars) and twelve months (red bars) old rTg-DI rats. Data 
shown are mean ± S.D of 6-7 rTg-DI rats per group. (K) rTg-DI rats showed consistently 
fewer return approaches within a session to four novel objects placed in an open field 
arena compared to WT rats at 3 and 12 months of age (*p < 0.05). 
 
Figure 3.   Analysis of Cerebral Microvascular A Deposition in rTg-DI Rats.  
Brain sections from rTg-DI rats at twelve months of age were immunolabeled with an 
antibody specific for A40 (red) (A) and an antibody specific for A42 (green) (B) and 
merged (C). Scale bar = 50 µm. (D) Cerebral microvessels were isolated from twelve 
months old rTg-DI rats and stained with thioflavin-S to visualize fibrillar amyloid deposits 
(green) and immunolabeled with an antibody to collagen IV to view the cerebral 
microvessels (red). Scale bar = 50 µm. (E) ELISA measurements were performed to 
determine the amounts of A40 and A42 in the microvessels isolated from rTg-DI rat 
brain.  Data shown are mean ± S.D. of 5 rTg-DI rats. (F) Cerebral microvascular amyloid 
deposits after digestion and removal of the capillaries and stained for fibrillar amyloid 
using thioflavin S (green). Scale bar = 50 µm.  (G) FTIR spectra in the region of the amide 
I vibration of vascular amyloid isolated from vessels of rTg-DI rat brain. (H) Thioflavin T 
fluorescence of fibril formation from seeds obtained from isolated vascular amyloid. 
Thioflavin fluorescence increases rapidly upon the addition of 100 M A40-WT monomer 
to sonicated vascular amyloid (black).  Monomeric A40-WT peptide exhibits a much 
slower increase in fluorescence in the absence of fibril seeds (blue).  (I) FTIR spectra in 
the region of the amide I vibration of A40-WT fibrils produced from seeds of the rat 
vascular amyloid.  The amide I vibration at 1632 cm-1 corresponds to -sheet.  The 
vibration at 1607 cm-1 corresponds to the amide vibration shifted as a result of 13C=O 
labels at the backbone carbonyls of Leu17, Ala21, Gly33 and Gly37. The large intensity 
of the 1607 cm-1 band relative to the -sheet vibration at 1632 cm-1 is characteristic of 
anti-parallel -sheet structure. The spectra were obtained after incubation for 48 h at 37 
°C. 
 
Figure 4. Cerebral Microvascular Structural Changes in rTg-DI Rats. 
Brain sections from wild-type rats (A) and rTg-DI rats (B) at twelve months of age were 
immunolabeled with an antibody to collagen IV to identify cerebral microvessels. Images 
shown are from the thalamic region of the rats. Numerous fragmented and string vessels 
(white arrows) were identified in the rTg-DI rats. Scale bars = 50 µm. (C) The tortuosity 
of the cerebral capillaries was measured in the cortex, hippocampus and thalamic region 
of wild-type and rTg-DI. Data shown are mean ± S.D. of 5-6 rats per group (***p < 0.001). 
(D) The capillary area was measured in the cortex, hippocampus and thalamic region of 
wild-type and rTg-DI. Data shown are mean ± S.D. of 5-6 rats per group (***p < 0.001).  
The data show that cerebral capillaries in rTg-DI rats exhibit structural abnormalities, 
increased tortuosity and, in the thalamic region, increased vascularization. 
 
Figure 5. Perivascular Glial Activation in rTg-DI Rats.   
Twelve months old brain sections from wild-type rats (A,C) and rTg-DI rats (B,D) were 
stained for fibrillar amyloid (blue), immunolabeled with an antibody to collagen IV to 
identify cerebral microvessels (red) and immunolabeled with an antibody to GFAP to 
identify astrocytes (green) (A,B) or immunolabeled with an antibody to Iba-1 to identify 
microglia (green) (C,D).  Scale bars = 50 µm. rTg-DI rats exhibit strong increases in 
perivascular reactive astrocytes and activated microglia in response to the prominent 
cerebral microvascular amyloid.  
 
Figure 6. Prominent Cerebral Microhemorrhages in rTg-DI Rats. 
Twelve months old brain sections from rTg-DI rats were stained for hemosiderin to identify 
microhemorrhages (blue) in the cortex (A), hippocampus (B) and the thalamus (C-F). 
Scale bars = 50 µm. The percent area fraction of hemosiderin staining was quantitated in 
the cortex, hippocampus and thalamus of six months old (gray) and twelve months old 
(red) rTg-DI rats (G). Data represent the mean ± S.D. of 6-7 rTg-DI rats per group. 
Progressive and consistent accumulation of microbleeds was observed, particularly in the 
thalamus, of rTg-DI rats. 
 
Figure 7. Progressive Cerebral Microvascular Occlusions in rTg-Rats. 
Twelve months old brain sections from rTg-DI rats were stained for hemosiderin to identify 
microhemorrhages (blue) and counterstained with pararosanline (pink) in the thalamus 
(A). Scale bar = 50 µm. Adjacent tissue sections were stained for calcium (black) and 
counterstained with pararosanline (pink) in the thalmus (B). Scale bar = 50 µm. Lower 
magnification revealed that the occluded, calcified microvessels were restricted to the 
thalamic region (C). Scale bar = 200 µm. The number of thalamic microvessel occlusions 
were counted in progressively aged rTg-DI rats (D). Data represent the mean ± S.D. of 5-
6 rTg-DI rats per group. Numerous occluded capillary/microvessels were observed 
around microbleeds specifically in the thalamic region of rTg-DI rats.  
 
Figure 8.  Detection of Microhemorrhage by MRI in rTg-DI Rats. (A) 2D T2*-weighted 
MRI (TE=7ms) matched to the corresponding Perl-stained histological slice (B). The 
dense dark areas in the thalamus shown on the T2*-weighted MRI (A) correspond to 
microvessels characterized by Perl stain-positive microbleeds and occluded vessels. (D) 
Perl-stained histological slice was overlaid on the T2*-weighted images under conditions 
where the histological slice have been rendered transparent to highlight the low signal 
intensity ‘susceptibility’ features on the T2*-weighted MRI observed bilaterally in the 
thalamus, which is caused by presence of hemosiderin. Scale bars = 500 µm. Panels (C) 
and (E) are higher magnification of the inserts in (B) and (D), respectively. Scale bars = 
100 µm. Panels (F) and (G) are 3D volume rendered MRIs of the same rat showing the 
brain outlined in light yellow; and the Perl stain-positive associated low signal intensity 
area in the thalamus have been volume rendered (green) to illustrate the near-perfect 
symmetry of the microhemorrhage/occluded microvessels areas. Scale bar = 3.5 mm. 
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